Cellceutix CEO Interview on TheStreetBeat Part II

The Street Beat Interview Series Cellceutix (CTIX)

Below is Part II of the CEO Interview from with Cellceutix CEO Leo Ehrlich, including the video and the text script.

Question:  I’d like to move on with you telling us a bit more about Prurisol.  What’s the current status?

As we disclosed recently, we have submitted pre-IND documentation to the FDA.  We recently received a response from the FDA confirming a mid-June meeting in which we will be discussing our goals for Prurisol. I would highly encourage anyone that has not seen the potency of Prurisol as a new psoriasis treatment to visit our website and look at the images that we made public showing how much more effective Prurisol was compared to methotrexate in our laboratory studies. (Editor’s Note: That webpage is here.)  Personally, I think the dramatic difference is phenomenal and showcases what we may have with this drug.

Question:  Finally, let’s touch on KM-391.  I recently saw that MIT had a breakthrough with autism research.  How do you see Cellceutix in this space?

We feel that we are positioned at the forefront of the industry.  There has been very limited research addressing the core issues of autism.  Sure, there are drugs that try to treat the symptoms and, honestly, with limited success.  Drugs that only treat the symptoms are not a solution, they are a Band Aid.  The recently released research at MIT showed that their experimental drug reversed some of the major symptoms of Fragile X syndrome in mice and that is fantastic news.  Fragile X is known to be leading cause of autism.  Similarly, we have tested our autism drug, KM-391, in mouse models where we have replicated many of the core symptoms of autism related to brain plasticity and serotonin levels.  Autism is a difficult disease to grasp at a root level.  To put it into more easily understood terms, often serotonin and plasticity levels are out of kilter; keeping neurons from “talking” to each other correctly.  It would be like the Tower of Babel, one person speaking Japanese to another person that speaks Chinese, to another person that speaks English, and on and on.  They don’t understand each other. When on certain tasks the communication is understood, we see the incredible ability that many autistic people have.  KM-391 helps with the reorganization and the road map to get everything in the right place so the neuron communications are correct.  In laboratory studies with KM-391, brain plasticity and serotonin levels returned to levels found in a non-autistic brain and measurable behavioral characteristics returned to normal.  It is very encouraging research.  As we move Kevetrin and Prurisol into clinical trials, we will be once again focusing on KM-391 and the advancement of it into human trials as well.

Merger and Acquisitions are happening regularly in the biotech world.  Do you see Cellceutix as a target for an acquisition?

I’m asked this quite regularly and it’s always a difficult question to answer.  There certainly have been some major deals recently with large amounts of money being paid for promising drugs that are still in development.  Gilead paid $11 billion for Pharmassets because of their Hepatitis C drug while it was still in trials.  Just last week, Human Genome Sciences rejected a $2.6 billion takeover bid from GlaxoSmithKline (GSK), whom analysts suspect was looking to get control of their heart disease drug that’s in clinical trials, amongst other things.  We already know that some of the biggest pharmas in the world are watching us.  We have planned for Kevetrin to begin trials at the most prestigious cancer center in the world.  In addition we were selected for other studies to be done in combination with the world’s largest pharma’s drugs, so we are getting the type of tremendous exposure that most other biotechnology companies can only dream of.  It’s not just haphazard or that we are just lucky.  We have an incredibly strong pipeline of drugs that can represent billions in sales each year if they make it to market.  Big pharma knows this and that’s why they are watching us.  The fact is once we are in clinical trials and if we get the positive results that we anticipate, then, yes, I would think that we would make a very attractive acquisition target to many large biotechs.

Thank you for your time, Leo.  Any parting words that you’d like to tell investors?

First off, thank you for having me.  It’s been a pleasure.  I’d just like to say that this is a very exciting time for Cellceutix and its shareholders.  We have reached many milestones already, but I believe that the real excitement is right around the corner.

Cellceutix (CTIX) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date, nor intends to be sold in the near term. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Dig-It Underground Stock Chart Analysis Video

Dig-It Underground Stock Chart Analysis Video(0)

A spike in volume and rise in share price has Dig-It Underground (Pink Sheets: DIGX) on the radar for more movement in the morning. A thinly-traded stock, volatility has been strong in the chart as the MACD trends upwards towards zero as the chart is making a bounce off the bottom. The Relative Strength Index

GelTech Receives First Order for FireIce from Turkey

GelTech Receives First Order for FireIce from Turkey(0)

GelTech Solutions, Inc. (OTCBB: GLTC) this morning reported receipt of the first order from Turkey through partner Nano Girisim Ltd. Sti.  Nano Girism Ltd. Sti., a distributor of industrial products based in Istanbul.  Nano Girisim intends to initially promote GelTech’s FireIce, a revolutionary water enhancing fire suppressant for use in fire extinguishers, as Turkish law

Lyris to Host Third Quarter Earnings Webcast

Lyris to Host Third Quarter Earnings Webcast(0)

Global digital marketing company Lyris, Inc. (OTCBB:LYRI) will report its operating results for the third quarter of fiscal 2012 on Thursday, May 10. The company will hold a conference call and webcast to discuss its financial results and operating activities open to all interested parties at 8 a.m., Pacific Daylight Time (11 a.m., Eastern Daylight

Athersys Meets with FDA to Discuss Suppressing GvHD in Leukemia and other Cancers

Athersys Meets with FDA to Discuss Suppressing GvHD in Leukemia and other Cancers(0)

Graft versus Host Disease (GvHD) is an area of great unmet medical that represents a significant risk to cancer patients throughout the world.  The condition occurs when patients receive a bone marrow transplant following radiation and/or chemotherapy, and the transplanted immune cells begin to attack the patient, causing significant pain and disability, or even death.

Judge Denies Taylor Armstrong’s Request to Dismiss Case with, Damages Could Grow in Excess of $3 Million

Judge Denies Taylor Armstrong’s Request to Dismiss Case with, Damages Could Grow in Excess of $3 Million(0)

In the latest round of the litigation between MMRGlobal, Inc. (OTCBB: MMRF) company (“MMR”) and Beverly Hills Housewife Taylor Armstrong, Los Angeles Superior Court Judge Frederick Shaller dealt a blow to Taylor Armstrong in denying her motion for a summary judgment to have the lawsuit against her dismissed. We first broke the story

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.